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Abstract
One of the primary contributors to the mortality of women is breast cancer. Several approaches are used to cure it, but
recurrence occurs in 79% of the cases because the underlying mechanism of the protein molecules is not carefully examined. The goal of this research was to use machine-learning tools is to elucidate conserved regions and to obtain
functional annotations of breast-cancer-related proteins. The sequences of five breast-cancer-related proteins (BRCA2,
BCAR1, BCAR3, BCAR4, and BRMS1) and their annotations were retrieved from the UniProt and TCGA databases,
respectively. Conserved regions were extracted using CLUSTALX. We constructed a phylogenetic tree using the
MEGA 7.0. SUPERFAMILY database to obtain fine-grained domain annotation. The tree revealed that the BRCA2 and
BCAR4 protein sequences are located in a clade, which indicates that they have overlapping functions. Several protein
domains were identified, including the SH2 and Ras GEF domains in BCAR3, the SH3 domain in BCAR1, and the
BRCA2 helical domain, the nucleic-acid-binding protein, and tower domain. We found that no protein domains could
be annotated for BCAR4 or BRMS1, which may indicate the presence of a disordered protein state. We suggest that
each protein has distinct functionalities that are complementary in regulating the progression of breast cancer, although
further study is necessary for confirmation. This protein-domain annotation project could be leveraged by the complete
integration of mapping with respect to gene and disease ontology. This type of leverage is vital for obtaining biochemical insights regarding breast cancer.
Keywords: breast cancer, breast-cancer-related protein, machine learning, protein annotation, sequence analysis

the development of highly accurate diagnostics [5].
Moreover, machine-learning models have been
employed to annotate medical informatics and
pharmacogenomics data to diagnose and provide
expert judgments regarding the progression of breast
cancer [6,7]. Based on recent research, several
mutations have been found in particular genes that
could play some part in the progression of breast
cancer. The most well-known genes are BRCA1 and
BRCA2, as the mutations of those genes have been
identified in breast-cancer cell-line samples [5,6].
Moreover, a transcriptomics biomarker is being
developed to detect the progression of triple-negative
breast cancer (TNBC) by leveraging its non-coding
(nc)RNA signatures [9].

Introduction
As reported by WHO, breast cancer is considered to be
one of the most dangerous diseases for women [1]. In
the United States, breast cancer is reported to comprise
15.2% of all the cancer cases and almost 7% of the
mortality rate [2]. A survey by the Ministry of Health of
Indonesia found that symptom of breast cancer are
detected in 2.6 of every 1000 breast lesion samples [3].
This disease has long been treated by conventional
means, i.e., surgery, radiation, and chemotherapy, which
are undertaken only after the cancer has entered a late
stage and has metastasized [4].
However, because the biomolecular mechanism of
breast cancer has been determined, the development of
more modern diagnostic approaches and therapeutics
are now feasible. Moreover, the field of molecular
medicine has employed the machine-learning approach
to diagnose the lesion images, metabolomics, genomics,
medical informatics predictors, and structural bioinformatics of breast cancer, which significantly facilitate

The development of transcriptomics-based diagnostics
and therapy is recognized as challenging, especially
with respect to clinical trials. In this regard, studying the
proteomics expression of breast cancer is expected to
provide significant relevant information. Several
proteomics-based breast-cancer drugs have been
101
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approved by the FDA, including Anastrozole®, which
targets hormone-receptor-positive (HR+) breast cancer,
Trastuzumab® for HER2-positive (HER2+) breast
cancer, and Fulvestrant (Faslodex®) for HR+ and
HER2-negative breast cancers with no hormone therapy
[8–10]. An exhaustive list is linked with the FDA
database that is available online [13]. As noted above,
combining molecular medicine with machine-learning
methods provides an interesting approach for obtaining
information about the–omics repertoire of breast cancer.
In this regard, the shortcoming of the machine-learning
method is the possibility of determining any introduction
of bias in the data annotations, which could introduce
redundancy in reports [14]. However, the advantages of
the machine-learning method for making gene or
protein annotations regarding breast cancer far outweigh
its shortcomings, i.e., mainly its ability to predict a finegrained molecular mechanism, its extensibility to broadrange–omics studies, and the provision of data
annotations for breast cancer survivors [15–17].
With respect to molecular proteomics, the protein
domain is widely recognized as an independent
molecular evolutionary unit that plays an important role
in cancer progression. An approach to structural
bioinformatics research has been devised that simulates
the molecular mutations in the TP53 and ER proteins
directly related to breast cancer [14,15]. The role of
disordered proteins and their phylogeny are also
computed. Moreover, to obtain complete populationsize samples of cancer patients, a dedicated database has
been developed, namely The Cancer Genome Atlas
(TCGA) [20]. The availability of this dedicated database
and the growing interest in proteomics research have
enabled the growth of machine learning-based tools for
annotating the occurrence of protein domains that have
a role in the progression of breast cancer [19–20]. This
method employs all the latest protein annotation or
proteomics tools. Notable proteomics databases such as
SUPERFAMILY, SCOP, and PFAM incorporate the
hidden Markov model method for predicting previously
unidentified protein domains and folds [21–23].
Moreover, the STRING database employs a graph
algorithm with a statistical probability model for
devising a nodes and edges repertoire [26]. In this
respect, the SUPERFAMILY protein domain database
was developed to provide annotations regarding the
progression of disease [27]. Based on the SCOP
classification that incorporates the machine-learning
approach of the SUPERFAMILY database, protein
domains are classified into families, superfamilies, and
folds. Protein families comprise domains with similar
sequences but different features, superfamilies comprise
domains with common ancestors, and folds comprise
domains with similar structures [26,27]. The SCOP
classification is the industry standard for protein domain
annotations.
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Several software packages and pipelines have been developed for making extensive domain annotations, and
these have attracted the interest of the scientific community [30,31]. This effort has been strengthened by the
more fine-grained annotation of protein–protein interaction networks of cancer-related proteins [30–32]. To this
end, these efforts should be solidified as a basis for developing a blueprint for constraining the menace of
breast cancer and developing drug designs for breast
cancer [34,35]. The development of proteomics information pipelines will facilitate the examination of the
protein domain repertoire in the progression of breast
cancer. The objective of this research is to use machinelearning tools to annotate the protein domains responsible for the progression of breast cancer. These annotations are expected to provide fine-grained information
for use in constructing a blueprint for the development
of drugs based on a complete analysis of proteomics
data regarding functional and conserved regions, with
annotations for TCGA-database-based proteins that represent a significant risk of breast cancer as the drug target. The reason protein sequences were examined rather
than genes is due to the availability of 3D structural data
that could shed a light on functional annotations.

Materials and Methods
Our choice of research methodology was inspired by
existing pipelines that have undergone significant
modifications with respect to existing indicators and
parameters [37,38]. This research was conducted using
a standard MacBook Pro Laptop with MacOSX
version 10.13.6, 512 GB of HDD, and 16 GB of RAM.
The employment of a Mac-based laptop was crucial
for leveraging a graphics subsystem with proven
scientific computation performance [39–42]. To navigate
and search for associations between genes and breast
cancer, the phrase ‘breast cancer’ was used to search
for the appropriate genes in the TCGA database
(https://portal.gdc.cancer.gov/). After identifying the
names of the genes, the associated protein sequences
were downloaded from the UNIPROT database
(https://www.uniprot.org/). All available sequence
retrieval procedures were utilized to obtain a
consensus regarding the sequences. The evolutionary
history was inferred using the maximum likelihood
(ML) method based on the Jones–Taylor–Thornton
(JTT) matrix-based model in the MEGA7 package,
along with its default parameters. The ML method was
chosen for its ability to iterate many different
evolutionary models to improve its reliability as a
general statistics model. Moreover, the ML method has
been proven to be the most accurate phylogenetic
method for estimating branch length and other
parameters [64,65]. The tree with the highest log
likelihood (1709.1737) was also identified. The
initial tree(s) for the heuristic search were obtained
automatically by applying the neighbor-join and BioNJ
June 2020  Vol. 24  No. 2
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algorithms to a matrix of pairwise distances estimated
using the JTT model and then selecting the topology
with the highest log-likelihood value. The tree is
drawn to scale, with branch lengths measured based on
the number of substitutions per site. The analysis
involved five amino-acid sequences. Positions with
less than 95% site coverage were eliminated. After the
construction of the tree, SUPERFAMILY and
STRING database searches were performed to
annotate the protein domains and their respective
interactions. For the SUPERFAMILY database search
(http://supfam.org/), the HMMSCAN significant Evalue hit was 0.03, whereas the reported E-value hit
was 1, which were leveraged as default values. Then,
as part of the SUPERFAMILY database project,
annotations of disordered proteins were searched using
the D2P2 database (http://d2p2.pro/), which only
provides hits with 100% identity. Thus, the minimum
required interaction score of the STRING database
(https://string-db.org/) is a medium confidence rating
(0.400, the default parameter) [41-49]. The downloaded
Protein Data Bank (PDB) files linked from the PFAM
database (http://pfam.xfam.org/) were visualized using
Chimera version 1.13.1 [54].

Results
The results are divided into five subsections with their
respective calculation times for each cycle in brackets,
i.e., protein sequence retrieval (10 minutes), protein
phylogeny (15 minutes), SUPERFAMILY domain
annotations (5 minutes), PFAM 3D annotations (5
minutes), STRING annotations (5 minutes), and the
disordered protein annotations (5 minutes), the last four
of which were obtained using machine-learning tools.
Protein sequence retrieval. The search for entries
regarding genes associated with breast cancer in the
TCGA database yielded the identification of five genes
with supporting references that are associated with a
significant risk of breast cancer and serve as drug
targets, namely BRMS1, BRCA2, BCAR1, BCAR3,
and BCAR4 [55–58]. As the TCGA mainly annotates
genes with complete population data, this does not mean
that other genes have no association with breast cancer.
They are simply not annotated because there is
insufficient population data for establishing a strong
association with the progression of breast cancer. To
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retrieve the protein sequences, the gene names were
simply queued into a search box in the UNIPROT
database (Table 1). As all of the proteins are associated
with the phrase “breast cancer” due to their importance
in the progression of this disease and their extensive
annotations in the TCGA database, it is interesting to
examine whether or not these proteins have a common
ancestor.
Protein phylogeny. Based on the UNIPROT database,
the respective protein function can be obtained by
accessing its annotations. The BRMS1 protein functions
as a translational repressor that regulates the antiapoptotic gene and inhibits the metastasic stage of
cancer. The function of the BRCA2 protein is to
regulate homologous recombination, avoid genomic
instability, and maintain the integrity of DNA repair
[59]. The function of the BCAR1 protein is to perform
docking for cell adhesion and migration, as well as to
mediate anti-estrogen resistance [60]. The function of
the BCAR3 protein is to regulate the signaling pathway
during the proliferation of breast cancer. Lastly, the
BCAR4 protein functions as an oncoprotein that induces
tamoxifen resistance to breast cancer. The aberration of
these genes has a significant influence on the progression
of breast cancer. To shed light on the clustering of these
proteins, we generated a phylogenetic tree by performing
a MEGA7 phylogenetic tree computation of the
proteins, as shown in Figure 1.

Figure 1.

Molecular Phylogenetic Analysis of BRCA2, BCAR1,
BCAR3, BCAR4, and BRMS1 by the Maximum Likelihood Method via the MEGA7 Application

Table 1. Breast-cancer-related Proteins from the UNIPROT Database
No.

Protein ID

1.

sp|Q9HCU9|BRMS1_HUMAN

2.

sp|P51587|BRCA2_HUMAN

Breast cancer type 2 susceptibility protein (BRCA2)

3.

sp|P56945|BCAR1_HUMAN

Breast cancer anti-estrogen resistance protein 1 (BCAR1)

4.

sp|O75815|BCAR3_HUMAN

Breast cancer anti-estrogen resistance protein 3 (BCAR3)

5.

tr|D3DUG6|D3DUG6_HUMAN

Makara J. Sci.

Description
Breast cancer metastasis-suppressor 1 (BRMS1)

Breast cancer antiestrogen resistance 4 (BCAR4)
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The results of our phylogeny analysis indicated that the
BRCA2 protein wass in the same cluster as the BCAR4
protein, although it was evident that the BCAR1 protein
is considered to be a distinct and unique cluster
relatively unrelated to other proteins. The phylogeny
analysis revealed an interesting domain cluster
consisting BRCA2
CA2 and BCAR4, both of which are
subjects of continuous drug development for breast
cancer. It could be true that these proteins were
clustered due to their extensive annotations in molecular
research, although a common molecular evolutionary
history may also play a part. It is also feasible that the
development of diagnostics and therapeutic agents
agent
involving these two protein domains are aligned to some
extent.
SUPERFAMILY domain annotation.. To annotate the
distribution of protein domains, we utilized the
SUPERFAMILY database. Figure 2 shows the domain
distribution of the five annotated breast-cancer-related
breast
proteins.
The BRCA2 protein was found to have two annotated
domains (Figure 2a), with the colored boxes in the
protein illustration representing different
erent domains. The
blue box is the BRCA2 helical domain (scop id of
81872), which has a SUPERFAMILY E-value
E
of 1.44e87. The red box indicates nucleic acid--binding proteins
(scop id of 50249), which have a SUPERFAMILY EE
value of 1.71e-45.
45. The BCAR1 protein belongs to one
annotated domain (Figure 2b), which is light blue in the
figure, representing the SH3-domain
domain (scop id of 50044)
with a SUPERFAMILY E-value
value of 3.54e-19.
3.54e
The
BCAR3 protein has two annotated domains (Figure 2c),
with the red box indicating the SH2 domain (scop id of
55550) with a SUPERFAMILY E-value
value of 4.58e-25
4.58e
and
the light blue box the Ras GEF domain (scop id of

48366) with a SUPERFAMILY E
E-value of 1.57e-36.
The E-value
value threshold for hit significance is a value
equal to or smaller than 10e-4.
4.
In the figure, we can see that there are no annotated
domains for either the BCAR4 or BRMS1 protein,
which are shown as straight lines in the protein model
(Figures 2d and 2e) and have E
E-values close to zero (0).
This means that the query results are very similar to the
template in the database, which indicates that the
designated protein domain has a highly probability of
existing. The descriptions in the SCOP database
regarding the function of these protein domains are
limited. Therefore, these outpu
outputs were extrapolated to
the PFAM database, which provides more detailed
descriptions. Moreover, the BCAR4 and BRMS1
proteins merit more attention to address the lack of
domain annotations. Too provide structural and
functional annotations for a protein doma
domain, 3D
structural data in the protein domain must be accessed
from both the PFAM and RCSB databases.
PFAM 3D annotation. The PFAM database provides
access to 3D-visualized
visualized annotations of the protein
domain, whereas the SUPERFAMILY with the SCOP
database lacks
acks this feature. The PDB file
file-based
visualization was obtained from the RCSB website,
which is directly linked with the PFAM database.
Homologous recombination repair, an important process
for cancer avoidance, is the main role of the BRCA2
protein in humans.. Both the under
under- and overexpression
of the BRCA2 protein are found in sporadic breast
breastcancer cases. The main feature of the BRCA2 helical
domain, which is the backbone of the BRCA2 protein,
is its helical and beta-hairpin
hairpin structure (Figure 3).

a.

b.

c.

d.

e.
Figure 2. Protein Domain Annotations of a) BRCA2, b) BCAR1, c) BCAR3, d) BCAR4/D3DUG6, and e) BRMS1 from S
SUPERFAMILY Database
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score with a maximum of 1, which indicates the most
intense interaction. In Figure 6a, we can see that the
protein that interacts with BRCA2 is PALB2, with an
interaction score of 0.99. PALB2 is as an auxiliary
protein for BRCA2 that assists with homologous repair
[61].. In Figure 6b, we can see that the protein that
interacts with BCAR1 is PXN, with an interaction score
of 0.999. The function of PXN is to assist with the
membrane attachment of the cytoskeleton protein.
Figure 6c shows that intense interaction has occurred
between the BCAR3 and BCAR1 proteins, with an
interaction score of 0.983. Figure
igure 6d shows interaction
between BRMS1 and ARID4A, with an interaction
score of 0.996. The function of ARID4A is to support
interaction with the retinoblastoma protein. There are no
annotations for the BCAR4 protein in the STRING
database. As such,
ch, we could not validate the occurrence
Figure 3. Annotated domain in the BRCA2 protein; the
BRCA2 helical, nucleic-acid
acid binding, and tower
domains (PDB ID: 1MIU) that share a common
structure. Visualized using Chimera version
1.13.1. Different colors represent different secse
ondary-structure folds (https://pfam.xfam.org/
https://pfam.xfam.org/
family/PF09169)

The BCAR3 protein comprises two domains, SH2 and
RAS GEF. The SH2 domain mainly regulates
regulat the signal
transduction and expression of oncoproteins, with
assistance from tyrosine kinases (Figure 4a). The RAS
GEF domain is a smart molecular switch that catalyzes
the hydrolytic reaction from guanosine triphosphate
(GTP) to guanosine diphosphate (GDP), which ensures
the balance of these biochemical species in the cell for
thee activation of the GTPase enzyme (Figure 4b).
The interaction between adaptor proteins and tyrosine
kinases is the primary feature of the SH3 domain, while
also acting as a mediator in the assembly of protein
complexes (Figure 5).

(a)

(b)

Figure 4. BCAR3 Protein with a) SH2 (PDB ID: 2cr4) and
b) RAS GEF Domains (PDB ID:6d52). Visua
Visualized using Chimera Version 1.13.1. Different
Colors Represent Differen
Different Secondary-structure
Folds (Source: https://pfam.xfam.org/family/sh2
and https://pfam.xfam.org/family/PF00617
https://pfam.xfam.org/family/PF00617)

In the PDB, the BRMS1 protein does not have a
complete structure, with only fragments of the NN
terminal region provided (http://www.rcsb.org/pdb/
http://www.rcsb.org/pdb/
results/results.do?tab toshow=Current&qrid=6E9CAA53).
toshow=Current&qrid=6E9
The BCAR4 protein also lacks a complete structure and
even any fragments in the PDB database. However, the
UNIPROT
database
provides
annotations
of
homologous information about these protein domains,
with slightly more detail at the domain level.
level The next
step was to identify protein–protein
protein interactions to
better understand the protein features.
STRING database annotations for protein–protein
protein
interaction. Protein–protein
protein interactions (PPIs) are
annotated in the STRING database. Figure 6 shows the
t
PPIs for the BRCA2, BCAR1, BCAR3, and BRMS1
proteins. The interaction intensity is expressed as a
Makara J. Sci.

Figure 5. BCAR1 Protein with SH3 Domain Visualized
using Chimera Version 1.13.1. Different Colors
Represent Different Secondary
Secondary-structure Folds
(Source: PDB ID: 6NMW and https://pfam.
xfam.org/family/PF00018
xfam.org/family/PF00018)
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of PPI between BCAR4 and BRCA2. However,
interaction may occur as in the phylogeny study they
were found to share the same protein cluster. Subtle
annotations could be the result of a disordered protein
feature, which is described in the next section. We note
that
at the proteins that interact with BCAR4, BRCA2,
BCAR1, and BRMS1 may have potential for being

leveraged for further study toward a rational drug design
because the latest biomedical research indicates that
they play important roles in the progression of bbreast
cancer [57,62–67].. In future work, consideration should
be given to whether genes are up
up- or down-regulated in
breast cancers.

a

b

c

d

Figure 6. Protein–protein Interactions of:: a) BRCA2, b) BCAR1, c) BCAR3, and d) BRMS1 ((https://string-db.org/)
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Figure 7. Disordered Protein Annotations for BRMS1. (Source: http://d2p2.pro
http://d2p2.pro)

Disordered protein database of SUPERFAMILY.
SUPERFAMILY
Next, we searched in the D2P2 database for the
signatures of disordered proteins without annotated
annot
domains. Since the existence of such a disordered
protein could be a indicated by the absence of proteinprotein
domain annotations, this would explain the lack of
result for the BCAR4 protein. However, there was a hit
for the BRMS1 protein (Figure 7). In this regard, all the
disorder predictors (PONDR VL-XT,
XT, PONDR VSL2b,
PrDOS, PV2, Espritz (all variants), IUPred (all
variants), and ANCHOR) showed significant hits in the
protein as signatures of disorders.
An explanation of the predictors is provided in a
published protocol [68].. Moreover, the top of Figure 7
shows three available isoforms for the BRMS1 protein.
BRMS1 is considered to be a disordered protein with no
annotated SUPERFAMILY domain, although it shows
hits in the PFAM domain, as indicated by the red block
in Figure 7. There is at least a 75% agreement among
different predictors, as shown by the green block with
the label ‘Predicted Disorder Agreement’. There are
also five post-translational
translational modifications of the protein
domain, as indicated by the ‘PTM sites’ label. These
results confirm that the BRMS1 protein is indeed
disordered.. Although the structural disorders
disorder of the
BCAR4 and BRMS1 proteins make their domain
information unavailable, we note that the 3-D
3 structures
of the proteins are intact and can still be used to
facilitate drug design. However, the missing domain
Makara J. Sci.

information
on could hamper our understanding of the
chemical bonds and our ability to obtain a more-detailed
resolution of the 3-D
D structure to identify what detracts
from the overall stability of the protein [69]. One
possible solution to this probl
problem would be to wait for
the next update to the structural disorde
disorders in the
SUPERFAMILY database.

Discussion
Due to the incompleteness of the domain annotations,
some possible strategies must be devised to address this
problem. A gene prediction package ccould be utilized to
leverage the existence of protein domains that provide
the function and the structure of these genes. Homology
modeling and ab-initio
initio methods could be used to predict
the structures of the BCAR4 and BRMS1 proteins,
which are feasible within
thin the boundaries of available
computational power. In our computational study, we
did not leverage any of the predicted data to determine
their degree of alignment with information generated by
wet laboratory research groups. As the indicators of
proteinn domain annotations, structural annotation, PPI,
and disordered proteins can shed light on both BCAR4
and BRMS1. More
ore research is needed in this area.
Moreover, using structural bioinformatics tools, the
feasibility of using the PPI partners of the annota
annotated
breast-cancer-related
related proteins as drug candidate targets
could be considered. Further research should be
conducted on proteins with unannotated domains as
June 2020  Vol. 24  No. 2
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possible signatures of a disordered protein. For proteins
without a clearly defined tertiary structure, the domain
repertoire should be annotated using a different
approach. This effort will be much more effective when
the SUPERFAMILY database has successfully
integrated its D2P2 disordered protein database into one
integrated platform. On this platform, strategies could
be developed to establish a disease ontology of the
protein domain. To this end, the relation between
protein domains, genes, and disease annotation could be
elucidated in finer detail.
Phylogenetic tree and PPI studies have shown that the
current molecular simulation protocol is insufficient for
effective drug design as proteome data has been used
without consideration of the networking context of the
interacting proteins. In the current approach, structural
bioinformatics studies are conducted with very limited
knowledge of PPIs or gene networks. To some extent,
solid knowledge about the protein domain repertoire is
subtly handled in structural annotations. Only indicators
that provide fine-grained annotations can be secured,
mainly from sequence retrieval and phylogenetic tree
studies. Annotations from other indicators should be
strengthened. To do so, advanced machine-learningbased tools or even deep-learning tools could be used to
facilitate completion of these annotations. Future
structural bioinformatics studies should incorporate a
more holistic approach to increase the success rate of
drug designs. The complexity of proteomics studies
remains daunting as protein domain rearrangement or
co-occurrence must be incorporated as the basis of
biomedical informatics studies and no method has yet
been developed to incorporate these data into the
structural bioinformatics approach.

Conclusion
Based on the results of this phylogenetic study, the
BCAR4 and BRCA2 proteins can be inferred to be in
the same cluster. Furthermore, the BCAR4 protein was
found to have no annotated domain in the
SUPERFAMILY, STRING, PDB, or D2P2 databases.
As such, to develop a blueprint for drug design,
determination of the correlation and interaction
between the BCAR4 and BRCA2 proteins will require
further in-depth annotations. Moreover, the absence of
SUPERFAMILY annotations for the BRMS1 protein
indicates that it may be in a disordered state. However,
STRING studies offer hope regarding the availability
of other proteins that could serve as targets for drug
design. This drug design effort would be made more
effective by incorporating the results of proteindomain rearrangement and co-occurrence studies using
more advanced machine-learning-based annotation
tools such as the gene prediction pipeline.
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